346
Participants
Start Date
January 24, 2018
Primary Completion Date
August 18, 2018
Study Completion Date
September 18, 2018
Selatogrel
Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) or matching placebo will be reconstituted with 1 mL of water for injection. Further dilution with 1 mL sodium chloride (NaCl) 0.9% will be performed for preparation of the dose of 8 mg selatogrel.
Placebo
Matching placebo for subcutaneous administration.
Selatogrel
Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
Rigshospitalet, Copenhagen
Aarhus University Hospital, Aarhus
Mount Sinai Hospital (New York), New York
Uppsala University Hospital, Uppsala
Inova Cardiology, Lutherville
Inova Center for Thrombosis Research and Translational Medicine, Falls Church
University of Florida (UF) Jacksonville, Jacksonville
Florida Hospital Tampa - Pepin Heart Institute, Tampa
Sahlgrenska University Hospital, Gothenburg
Indiana University School of Medicine - Krannert Institute of Cardiology, Indianapolis
NorthShore University, Chicago
Universitats-Herzzentrum, Bad Krozingen
National Heart Centre Singapore, Singapore
Institut de Cardiologie de Montréal, Montreal
University Medical Center Groningen, Groningen
Maastricht UMC, Maastricht
St. Antonius Ziekenhuis, Nieuwegein
Freeman Hospital - Cardiothoracic Department, Newcastle upon Tyne
Sheffield Teaching Hospitals, Sheffield
East & North Hertfordshire NHS Trust - Lister Hospital, Stevenage
Viatris Innovation GmbH
INDUSTRY